MDA7/IL-24 is an anti-viral factor that inhibits influenza virus replication.
Melanoma differentiation associated gene-7 (mda-7)/interleukin- 24 (IL-24) is a secreted cytokine, which plays an essential role in tumor suppression. Although its role as a multifunctional protein affecting broad types of cancers is well described, functions of IL-24 in host defense against virus infection are yet to be determined. In this study, we explored the anti-viral effect of recombinant IL-24 treatment during influenza infection. Infection of human lung adenocarcinoma cells (A549) with the influenza A virus up-regulated IL-24 mRNA and protein expression in a time-dependent manner. Pre-treatment of A549 cells with recombinant IL-24 protein effectively suppressed viral plaque formation. Furthermore, IL-24 treatment of A549 cells reduced viral non-structural protein 1 (NS1) synthesis, whereas IL-24 knockdown resulted in increased viral replication. Interestingly, IL-24 treatment following influenza A virus infection led to up-regulation of interferon (IFN)-induced antiviral signaling. Taken together, our results suggest that IL-24 exerts a potent suppressive effect on influenza viral replication and can be used in the treatment of influenza infection.
Brain Korea 21 Plus for Biomedical Science, College of Medicine, Korea University, Seoul, 08308, Republic of Korea.
Rak-Kyun
RK
Seong
College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, 28644, Republic of Korea.
Young-Ki
YK
Choi
Brain Korea 21 Plus for Biomedical Science, College of Medicine, Korea University, Seoul, 08308, Republic of Korea. oshin@korea.ac.kr.
Ok Sarah
OS
Shin
D015088:2',5'-Oligoadenylate Synthetase / Q000235:genetics; D000072283:A549 Cells; D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D055785:Gene Knockdown Techniques; D006801:Humans; D009980:Influenza A virus / Q000187:drug effects* / Q000502:physiology; D007251:Influenza, Human; D007378:Interleukins / Q000235:genetics / Q000494:pharmacology*; D064547:Myxovirus Resistance Proteins / Q000235:genetics; D011994:Recombinant Proteins / Q000494:pharmacology; D015398:Signal Transduction / Q000235:genetics; D015854:Up-Regulation; D017361:Viral Nonstructural Proteins / Q000235:genetics; D010948:Viral Plaque Assay; D014779:Virus Replication / Q000187:drug effects*; D000099180:Interleukin-24
D015088:2',5'-Oligoadenylate Synthetase; D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007378:Interleukins; D064547:Myxovirus Resistance Proteins; D011994:Recombinant Proteins; D017361:Viral Nonstructural Proteins; D000099180:Interleukin-24; C579071:MX1 protein, human
IL-24; antiviral activities; influenza
Oncogene. 2003 Feb 27;22(8):1164-80
12606943
Oncogene. 1995 Dec 21;11(12):2477-86
8545104
J Microbiol. 2012 Apr;50(2):359-62
22538668
Immunology. 2005 Feb;114(2):166-70
15667561
Antiviral Res. 2015 Nov;123:93-104
26367324
Cancer Res. 2005 Nov 15;65(22):10128-38
16287994
Mol Ther. 2005 Jan;11(1):160-72
15585417
Semin Pediatr Infect Dis. 2002 Apr;13(2):120-8
12122950
Mol Med. 2001 Apr;7(4):271-82
11471572
Sci Rep. 2015 Nov 18;5:16512
26576844
Annu Rev Immunol. 2014;32:513-45
24555472
JAMA. 2007 Apr 4;297(13):1435-42
17405969
Virology. 1998 Dec 20;252(2):324-30
9878611
Mol Ther. 2005 Jan;11(1):149-59
15585416
Cancer Res. 2003 Dec 1;63(23):8138-44
14678967
Mol Cancer Ther. 2003 Jul;2(7):623-32
12883035
Cancer Biol Ther. 2003 Jul-Aug;2(4):347-53
14508103
Oncogene. 2001 Oct 25;20(48):7051-63
11704829
Curr Top Microbiol Immunol. 2014;385:359-75
24990620